{"nctId":"NCT02131636","briefTitle":"Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea","startDateStruct":{"date":"2014-05"},"conditions":["Erythema","Rosacea"],"count":440,"armGroups":[{"label":"AGN-199201","type":"EXPERIMENTAL","interventionNames":["Drug: AGN-199201"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle to AGN-199201"]}],"interventions":[{"name":"AGN-199201","otherNames":[]},{"name":"Vehicle to AGN-199201","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Moderate to severe persistent facial erythema associated with rosacea.\n\nExclusion Criteria:\n\n* Greater than 3 inflammatory lesions on the face\n* Current treatment with monoamine oxidase (MAO) inhibitors\n* Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales","description":"The investigator assessed the patient's overall severity of erythema in the treatment area on the 5 point CEA scale (ranging from 0=clear skin with no signs of erythema to 4=severe erythema/fiery redness). The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) on both CEA and SSA from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With at Least a 2-Grade Decrease From Baseline on the SSA 5-point Scale","description":"The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)","description":"Rosacea facial redness in the treatment area was measured by DIA. The percent change was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. Baseline was defined as the measurement at predose on Day 1. A negative number change from baseline indicates a decrease in facial redness (improvement), and a positive number change from baseline indicates an increase in facial redness (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.37","spread":"94.693"},{"groupId":"OG001","value":"61.54","spread":"428.943"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.22","spread":"97.835"},{"groupId":"OG001","value":"75.09","spread":"498.844"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.00","spread":"92.893"},{"groupId":"OG001","value":"71.18","spread":"398.072"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.35","spread":"98.547"},{"groupId":"OG001","value":"74.16","spread":"415.301"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Reporting Treatment Satisfaction on the Satisfaction Assessment for Rosacea Facial Redness (SA-RFR) Questionnaire Item 9","description":"The SA-RFR questionnaire item 9 is completed by patients assessing treatment satisfaction on facial redness. Patients reporting treatment satisfaction as \"very satisfied\" or \"satisfied\" are noted. The percentage of patients was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"27.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"23.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9","spread":null},{"groupId":"OG001","value":"24.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the SA-RFR Questionnaire Item #4","description":"The SA-RFR questionnaire item 4 is completed by patients assessing how much their face burned due to facial redness on a 5 point scale (range 0=does not burn at all and 4=burns a lot). Patients were evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. A lower score change from baseline (negative number) indicates a decrease in facial redness (improvement), and a higher score change from baseline (positive number) indicates an increase in facial burning (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.83"},{"groupId":"OG001","value":"1.9","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.93"},{"groupId":"OG001","value":"-1.5","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.91"},{"groupId":"OG001","value":"-1.5","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.97"},{"groupId":"OG001","value":"-1.5","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.97"},{"groupId":"OG001","value":"-1.5","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale","description":"The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 1 grade decrease (improvement) on the SSA from baseline at Day 1 hour 1. Baseline was defined as the measurement at predose on Day 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":222},"commonTop":[]}}}